Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 707-713

  Melichar, Bohuslav ^a,b   Patenia, Rebecca ^b   Gallardo, Stacie ^b   Melicharová, Karolina ^a   Hu, Wei ^b   Freedman, Ralph S ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

cD40; cD40 ligand; Ovarian cancer

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; GAMMA1B INTERFERON; RECOMBINANT PROTEIN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD40; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD40 LIGAND; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA, RECOMBINANT; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33846916705     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.056     Document Type: Article

References (44)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer Statistics. CA Cancer J. Clin. 54 (2004) 8-29
2. van Kooten C., and Banchereau J. CD40-CD40 ligand. J. Leukocyte Biol. 67 (2000) 2-17
3. Hayward A.R., Levy J., Facchetti F., Notarangelo L., Ochs H.D., Etzioni A., et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 158 (1997) 977-983
4. Tong A.W., Papayoti M.H., Netto G., Armstrong D.T., Ordonez G., Lawson J.M., et al. Growth-inhibitory effects of CD40L (CD154) and its endogenous expression in human breast cancer. Clin. Cancer Res. 7 (2001) 691-703
5. Aukrust P., Muller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Circulation 100 (1999) 614-620
6. Morris A.E., Remmele R.L., Klinke R., Macduff B.M., Fanslow W.C., and Armitage R.J. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J. Biol. Chem. 274 (1999) 418-423
7. Hirano A., Longo D.L., Taub D.D., Ferris D.K., Young L.S., Eliopoulos A.G., et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93 (1999) 2999-3007
8. Posner M.R., Cavacini L.A., Upton M.P., Tillman K.C., Gornstein E.R., and Norris C.M. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin. Cancer Res. 5 (1999) 2261-2270
9. Eliopoulos A.G., Davies C., Knox P.G., Gallagher N.J., Afford S.C., Adams D.H., et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol. Cell. Biol. 20 (2000) 5503-5515
10. Gallagher N.J., Elipoulos A.G., Agathangelo A., Oates J., Crocker J., and Young L.S. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol. Pathol. 55 (2002) 110-120
11. Ghamande S., Hylander B.L., Oflazoglu E., Lele S., Fanslow W., and Repasky E.A. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 61 (2001) 7556-7562
12. Vonderheide R.H., Dutcher J.P., Anderson J.E., Eckhardt S.G., Stephans K.F., Razvillas B., et al. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19 (2001) 3280-3287
13. Freedman R.S., Bowen J.M., Leibovitz A., Pathak S., Siciliano M.J., Gallager H.S., et al. Characterization of an ovarian carcinoma cell line. Cancer 42 (1978) 2352-2359
14. Auzenne E., Donato N.J., Li C., Leroux E., Price R.E., Farquhar D., et al. Superior therapeutic profile of poly-l-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin. Cancer Res. 8 (2002) 573-581
15. Buick R.N., Pullano R., and Trent J.M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45 (1985) 3668-3676
16. Andrews P.A., and Albright K.D. Mitochondrial defects in cis-diamminedichloridplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 52 (1992) 1895-1901
17. Melichar B., Ferrandina G., Verschraegen C.F., Loercher A., Abbruzzese J.L., and Freedman R.S. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin. Cancer Res. 4 (1998) 3069-3076
18. Nash M.A., Lenzi R., Edwards C.L., Kavanagh J.J., Kudelka A.P., Verschraegen C.F., et al. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocytes (TIL)-derived T cell lines and established tumour cell lines. Clin. Exp. Immunol. 112 (1998) 172-180
19. Melichar B., Nash M.A., Lenzi R., Platsoucas C.D., and Freedman R.S. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumor infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin. Exp. Immunol. 119 (2000) 19-27
20. Deng J., Xia W., and Hung M.C. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene 17 (1998) 2167-2175
21. Lenzi R., Rosenblum M., Verschraegen C., Kudelka A.P., Kavanagh J.J., Hicks M.E., et al. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin. Cancer Res. 8 (2002) 3686-3695
22. Voorzanger-Rousselot N., Favrot M.C., and Blay J.Y. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 92 (1998) 3381-3387
23. Pirozzi H., Lombari V., Zanzi D., Ionna F., Lombardi M.L., Errico S., et al. CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. Int. Immunol. 12 (2000) 787-795
24. Sabel M.S., Yamada M., Kawaguchi Y., Chen F.A., Takita H., and Bankert R.B. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol. Immunother. 49 (2000) 101-108
25. Sugimoto K., Shiraki K., Ito T., Fujikawa K., Takase K., Tameda Y., et al. Expression of functional CD40 in human hepatocellular carcinoma. Hepatology 30 (1999) 920-926
26. Grell M., Zimmermann G., Gottfried E., Chen C.M., Grunwald U., Huang D.C.S., et al. Induction of cell death by tumor necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 18 (1999) 3034-3043
27. Hess S., and Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med. 183 (1996) 159-167
28. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N. Engl. J. Med. 344 (2001) 783-792
29. Eliopoulos A.G., Dawson C.W., Mosialos G., Floettmann J.E., Rowe M., Armitage R.J., et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1:involvement of TRAF3 as a common mediator. Oncogene 13 (1996) 2243-2254
30. Hayashi T., Treon S.P., Hideshima T., Tai Y.T., Akiyama M., Richardson P., et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br. J. Haematol. 121 (2003) 592-596
31. Tai Y.T., Catley L.P., Mitsiades C.S., Burger R., Podar K., Shringpaure R., et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 64 (2004) 2846-2852
32. Todryk S.M., Tutt A.L., Green M.H.A., Smallwood J.A., Halanek N., Dalgleish A.G., et al. CD40 ligation for immunotherapy of solid tumours. J. Immunol. Methods 248 (2001) 139-147
33. Kelley S.K., Gelzleichter T., Xie D., Lee W.P., Darbonne W.C., Qureshi F., et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br. J. Pharmacol. 148 (2006) 1116-1123
34. Alderson M.R., Armitage R.J., Tough T.W., Strockbine L., Fanslow W.C., and Spriggs M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. 178 (1993) 669-674
35. Imaizumi K., Kawabe T., Ichiyama S., Kikutani H., Yagita H., Shimokata K., et al. Enhancement of tumoricidal activity of alveolar macrophages via CD40-CD40 ligand interaction. Am. J. Physiol. 277 (1999) L49-L57
36. Diehl L., Den Boer A.T., Schoenberger S.P., va der Voort E.I.H., Schumacher T.N.M., Melief C.J.M., et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5 (1999) 774-779
37. Borges L., Miller R.E., Jones J., Ariail K., Whitmore J., Fanslow W., et al. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J. Immunol. 163 (1999) 1289-1297
38. Chin Y.E., Kitagawa M., Su W.C.S., You Z.H., Iwamoto Y., and Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science 272 (1996) 719-722
39. Burke F., Smith P.D., Crompton M.R., Upton C., and Balkwill F.R. Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA. Br. J. Cancer 80 (1999) 1236-1244
40. Nguyen V.T., and Benveniste E.N. Involvement of STAT-1 and its family members in interferon-gamma induction of CD40 transcription in microglia/macrophages. J. Biol. Chem. 275 (2000) 23674-23684
41. Suk K., Chang I., Kim Y.H., Kim S., Kim J.Y., Kim H., et al. Interferon-γ (IFNγ) and tumor necrosis factor a synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNγ inhibits cytoprotective NF-κN through STAT1/IRF-1 pathways. J. Biol. Chem. 276 (2001) 13153-13159
42. Burke F., Knowles R.G., East N., and Balkwill F.R. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int. J. Cancer 60 (1995) 115-122
43. Melichar B., Hu W., Patenia R., Melicharova K., Gallardo S.T., and Freedman R. rINF-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. J. Transl. Med. 1 (2003) 5
44. Pujade-Lauraine E., Guastalla J.P., Colombo N., Devillier P., Francois E., Fumoleau P., et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. 14 (1996) 343-350